Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL Believe
2022-001191-34Phase 2Active
- Sponsor
- Ascendis Pharma
- Start
- Jan 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of TransCon IL-2 β⁄γ in Non-hematologic malignancy, ovarian cancer, melanoma and 2 more (5 arms), sponsored by Ascendis Pharma. Primary endpoints: Treatment-emergent adverse events, Treatment-related adverse events and 3 more. Started Jan 2023; status: active.
02
Drugs
TransCon IL-2 β⁄γ
03
Conditions
Non-hematologic malignancyovarian cancermelanomaCervical Cancer (CC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001191-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001191-34.